Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
The mechanism of action of recombinant factor VIIa (rFVIIa), i.e. increased thrombin generation on the membrane of activated platelets, as well as the results from in vitro and ex vivo models of thrombocytopenia or inherited thrombocytopathia may support some potential of rFVIIa in thrombocytopenia/thrombocytopathia. rFVIIa was reported as effective to stop or to decrease bleeding in few patients with severe thrombocytopenia resistant to platelet transfusions; however data are still scarce and clinical studies are really needed to define efficacy/safety ratio as well as optimal treatment regimen in this potential indication. Some data in patients with Glanzmann thrombasthenia (GT) may support the use of rFVIIa outside its primary indication in the cases in which there is no real treatment alternative (GT patients with antibodies to GP IIb-IIIa or with platelet refractoriness).
Laurian
Yves
Y
Novo Nordisk Pharmaceutique SA, Boulogne-Billancourt, France. yvla@novonordisk.com
D001606:Bernard-Soulier Syndrome / Q000188:drug therapy; D001791:Blood Platelet Disorders / Q000150:complications / Q000188:drug therapy*; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013915:Thrombasthenia / Q000188:drug therapy; D013921:Thrombocytopenia / Q000188:drug therapy
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa